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 
Abstract – Schistosomiasis, a disease caused by the 
trematodes of the Schistosoma genus, affects about 240 
million people worldwide. The Praziquantel (PZQ) is the 
drug used to treat this disease. However, reports of 
resistant strains reinforce the need to develop a new 
schistosomicidal drug. The study of new drugs and vaccines 
that can contribute to the control of this pathology becomes 
urgent. A new approach can be held by the study of the 
following Schistosoma mansoni enzymes: purine nucleoside 
phosphorilase 1 (PNP), hypoxanthine guanine 
phosphoribosyltransferase (HGPRT) and adenylate kinase 
1 (ADK). The parasite, incapable of synthetizing purine 
nucleotides through the de novo pathway, has multiple 
mechanisms to incorporate purine bases through the 
purine salvage pathway. Our goal was to assess, through 
immunoenzimatic assay (ELISA-indirect), the production 
of total IgG, IgE and IgG2a in the plasma after 
immunization with the PNP, HGPRT and ADK enzymes, 
using the S. mansoni cercariae – infected murine model. 
Our results showed that the immunization in Balb/c mice 
with the enzymes mentioned above induced production of 
the immunoglobulines at the 48
th 
and 85
th
 days, 
post-infection. Thereby, new assays must be made for a 
better assessment on how these enzymes modulate an 
immune response.  
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I. INTRODUCTION 
 
According to the World Health Organization (WHO), on 
tropical and subtropical areas, schistosomiasis is the second 
parasitic disease of greater prevalence, in terms of morbidity 
and mortality, surpassed only by malaria. Currently, 
approximately 779 million individuals live at risk areas, in 77 
countries where schistosomiasis caused by different species is 
endemic and 55 countries endemic only to the schistosomiasis 
mansoni, including Brazil [1]. Schistosomiasis is caused by a 
platyhelminthes of the Schistosoma genus, which affects the 
poorest communities of underdeveloped and emergent 
countries [2]. In the last 30 years, no drugs have been developed 
for schistosomiasis [3,4] being the administration of 
Praziquantel (PZQ) the current treatment for schistosomiasis 
mansoni recommended by WHO. However, PZQ is practically 
inactive against immature schistosomula, besides presenting 
mutagenic and teratogenic collateral effects and favoring the 
resistance growth of the lineages [5]. The S. mansoni is a 
complex organism. The study of its genetic and biochemical 
aspects, besides providing information about its biology, is a 
great source of interest to the investigations of new vaccines 
and drugs [6]. During its development, the S. mansoni is 
exposed to different micro-environments, what makes it go 
through morphological modifications and physiological 
transformations, as the change in the expression of some genes. 
The parasite is covered by a syncytium layer, called tegument. 
The tegument has some proteins that act as a barrier, providing 
protection to the plasmatic membrane of the parasite against the 
attack of the immunity of the host [7]. The characterization of 
the specific proteins of the tegument is especially interesting 
because these proteins are the first to be presented to the 
immune system of the host, what makes them a possible target 
to the development of vaccines [6]. The parasites induce a low 
natural immunity and they are able to evade or resist to the 
specific immune responses of the hosts. The dissemination of 
the disease are even more accentuated by the lack of 
infrastructures of water resources, absence of sanitary 
education, and deficiency in people’s education concerning the 
domestic and hygienic habits [8]. Having this context in mind, 
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the study of the enzymes that participate in the S. mansoni 
essential pathways can be quite promising to develop specific 
tools to control this disease. The nucleotides of purines are 
required in all the organisms to DNA and RNA synthesis. 
These nucleotides can be obtained by the de novo synthesis or 
by the salvage pathway of the purines. The de novo pathway 
uses simple precursors to the synthesis of various nucleotides. 
On the other hand, the salvage pathway of purines is the 
reutilization of pathways by which the organism can satisfy its 
requirement of pre-formed purines [9]. One of the advantages 
of the salvage pathway is the fact that the de novo pathway 
requires a big quantity of energy to the purine bases [10]. 
Different from its human host, the S. mansoni depends entirely 
on the salvage pathway of purines to feed its demand of purine 
bases [11]. Another factor that contributes to this research is the 
fact that the literature does not have sufficient data to respond to 
the questions about the mechanisms of action of these enzymes. 
Concerning the enzymes that act in an intracellular manner, it 
was not found scientific works that can prove their exposition 
or secretion by the S. masoni. Thus, essential enzymes to the 
parasite can be promising study subjects. The enzymes purine 
nucleoside phosphorilase 1 (PNP) (EC 2.4.2.1), hypoxanthine 
guanine phosphoribosyltransferase (HGPRT) (E.C 2.4.2.8)  and 
adenylate kinase 1 (ADK) (E.C 2.7.4.3) are cytoplasmic 
enzymes and its exposure in the adult worm’s tegument were 
not yet confirmed. However, there are studies which reports 
secretion of one of the enzymes constituent of the S. mansoni 
purine salvation pathway, the nucleoside-diphosphate kinase 
(NDPK), by prokaryote pathogens, as demonstrated by 
Zaborina [12], in which was observed secretion of this enzyme 
by Mycobacterium bovis e Pseudomonas aeruginosa bacteria, 
as well as Punj [13]. Recently a group of collaborators with this 
study (IFSC-USP) showed that the structures of the PNP, 
HGPRT and ADK enzymes do not present any risk regarding 
the immunization in human beings: the highest percentages of 
homology were between 30-50% of identity with the same in 
human beings.  Nevertheless, in order to happen an 
immunological response, it is necessary to have some 
accessible factors (antigens exposed) and these external 
antigenic  factors are the first to be recognized; with the time 
being, with the destruction of some of the antigens, more 
internal factors can be expressed or excrete physiologically. 
The innate immune system is able to recognize antigenic parts 
present in the pathogen surfaces known as PAMPs 
(Pathogen-Associated Molecular Pattern) and then the first 
patterns of immunological response against the pathogen is 
initiated. The pathogenesis of the schistosomiasis mansoni is 
dependent on the human interaction with the helminth. 
Concerning the S. mansoni, the strain, the evolutive phase, the 
intensity and the number of infections are important. In relation 
to the host, the genomics constitution, organ predominantly 
damaged, feed pattern, ethnicity, reactivation of the disease, 
specific treatment, other infections. The acute phase is divided 
into two evolutive periods: the pré-patent (before the 
oviposition and the post-patent after the oviposition. Although 
the immunological mechanisms involved in the response of the 
acute infection are not yet completely elucidated, some 
investigations in murine models showed that there is in the 
beginning a predominance of an immune response type Th1, 
substituted by Th2 in the post-patent phase[14]. During the 
pre-patent phase, plasmatic levels considered of tumor necrosis 
(TNF) and of Interleukins 2 and 6 produced by the 
mononuclear cells are detected [15]. It is believed that the 
immune response type Th1 is responsible for the damages in 
the tissues and the clinic manifestations in the acute phase. 
Another interesting aspect is the cellular cytotoxicity dependent 
on the antibodies (ADCC), with effector action on 
schistosomula. Recently the Oswaldo Cruz Institute (IOC), 
located in Rio de Janeiro, Brazil developed and patented the 
first vaccine to the schistosomiasis in the world. The vaccine, 
approved by the National Agency of Sanitary Supervision 
(ANVISA/Brazil), proved to be safe and able to immunize 
human beings against the disease. It also proved to be efficient 
against fascioliasis and it can be used in the future to avoid the 
contamination by other types of worms. As other vaccines, the 
national dose was produced from an antigen Sm14, being part 
of the fatty acid-binding proteins [16]. Besides the 
schistosomiasis, many other studies with antigen purified from 
other parasites are being tested in other experimental models as 
candidates to the immunizations. Some of them present 
promising results, as the one that uses the model with primates 
where the immunization with the protein MSP1 of Plasmodium 
cynomolgi resulted in high levels of antibodies and the decrease 
of the blood parasite charge after the challenge [17]. The study 
by PENG [18] that showed in serums of rabbits infected with 
cercarie Schistosoma japonicum a positive immune response 
with the enzyme adenilato kinase, enzyme that also participates 
in the salvage pathway of purines. In 2008, the RNAi technique 
reinforced the importance of the enzyme (HGPRT) to the 
survival of the parasite. Small RNAs of interference (RNAis) 
were produced against HGPRT, injected after 70 days of 
infection with cercariae in mice. The number of worms was 
counted six days after the injection.  The total number of 
parasites was reduced in approximately 27% after the 
treatement [19]. The development of a vaccine, together with 
the treatment, would be a promising way of fighting and 
controlling schistosomiasis [20]. Two kinds of pathways lead to 
nucleotide synthesis in the living beings: de novo and salvation 
pathways. The de novo pathways for purine and pyrimidine 
biosynthesis are similar in practically every living organism 
and have as metabolic precursors: amino acids, ribose 5- 
phosphate, CO2 e NH3 [21]. The salvation pathways are the 
reutilization of nucleosides (without the phosphate group) that 
were released from the break of nucleic acids. These two kinds 
of pathways are important for the cellular metabolism [21, 22]. 
Thus, one of the advantages of the salvation pathway is that it 
requires less amount of energy for purine bases synthesis, 
compared to the de novo pathway. In S. mansoni, [11] have 
demonstrated, in their work about purine metabolism, a fast 
adenine incorporation in nucleotides and were not able to 
establish 14C-glycine and 14C-glucose incorporation in the 
purine ring. This fact shows great dependence of an external 
supply of pre-formed bases for nucleotide synthesis, as shown 
by the loss of the purine synthesis of the de novo pathway. The 
PNP is an enzyme that reversibly catalyzes the phosphorylase 
purine nucleoside in order to generate the purine base and 
ribose-1- phosphate and it has been descripted as participant in 
the S. mansoni salvation purine pathway with the sole purpose 
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of supplying purine bases used in the ADN and RNA synthesis 
[11,23] . It is important to notice that, in Schistosoma adult 
worms [23] and schistosomula (immature form) [24], unlike its 
mammal hosts, the worms are not able to synthesize purine 
nucleosides and depend solely on the salvation pathway to its 
purine necessities. Two isoforms were identified in the 
parasite’s genome, named SmPNP1 e SmPNP2. The 
SmPNP1was the first salvation pathway enzyme which was 
cloned, expressed, purified, crystallized and had its structure 
resolved [25,26]. The SmPNP1 has 287 amminoacids, being a 
trimer in solution and in crystal form. A second coding gene to 
another isoform for the SmPNP was identified on the S. 
mansoni Genome Project: The SmPNP2, which has 61,8% of 
identity, when compared to SmPNP1 and coded to a protein 
with 299 amminoacids, being greater than SmPNP1. The 
HGPRT enzyme catalyzes the reversible phosphorylation from 
hypoxanthine and guanine to inosine monophosphate or 
guanosine monophosphate, respectively, and pyrophosphate 
using as phosphate and ribose donor the 5-phosphoribosyl- 
diphosphate (PRPP). Studies on S. mansoni schistosomula 
indicates that organisms basically depends on the purine bases 
retrieval in order to ensure its purine nucleotide needs [27]. Due 
to limited interconversion between adenine and guanine 
nucleotides, the S. mansoni HGPRTase provides the main 
sources of guanine nucleotides for the parasite. The HGPRT 
enzyme has been found usually as a dimer in solution on 
Tritrichomonas foetus (HGXPRT) [28] Trypanosoma cruzi, 
Trypanosoma brucei, Leishmania donovani [29] and 
Leishmania tarentolae [30] organisms. It is found in the 
tetramer form in solution on Escherichia coli (HPRT) [31], 
Toxoplasma gondii (HGXPRT) [32], Plasmodium falciparum 
(HGXPRT) [33] and on human enzyme [34]. Three 
homologous genes for the HGPRT (Smp_148820, 
Smp_168500, Smp_103560) were found at the parasite’s 
genome, which are related with the parasite’s different life 
stages. This enzyme has 48% of identity, when compared to the 
human homolog and demonstrated several properties that 
distinguishes it from mammal’s enzymes [27]. 
Adenylate Kinase (ADK) is an enzyme that is involved in 
cellular homeostasis, energetic metabolism and nucleotide 
synthesis. The enzyme catalyzes the ATP (Adenosine 
triphosphate) + AMP Adenosine monophosphate ƒ´ 2 ADP 
(Adenosine diphosphate) reaction. It is known that several 
ADK are found in mammals, as the skeletal muscle is 
particularly rich in ADK1, main provider of isoforme 
citosolica.[35]. There have been reports that its deficiency in 
humans may cause light Hemolytic anemia [36]. The ADK1 
(Smp_071390) codes to a protein with 197 amminoacids and 
has 54% of identity, when compared to the human ADK1 
The study of Peng [18] has shown that immunization with the 
Schistosoma japonicum ADK enzyme was capable of 
stimulating the antibodies production against S. japonicum, 
revealing a positive immune response post-immunization. Thus, 
reinforcing this hypothesis, our study aimed to assess whether 
purine salvation pathway enzymes (PNP, HGPRT and ADK), 
when used as immunizing, associated to the aluminum 
hydroxide adjuvant, stimulate a specific immune response 
which favors the S. mansoni antigens recognition. Hence, our 
study, in a novel approach, intends to assess whether S. 
mansoni PNP, HGPRT and ADK enzymes can, in future, be 
candidates for a vaccine against this disease, since that, to date, 
no study has been made using such enzymes, isolated from S. 
mansoni, in mice immunization during experimental 
schistosomiasis mansoni. Thereby, we state the hypothesis that 
these enzymes, by mechanisms yet unknown, seem to modulate 
the infection by Schistosoma in different species of rodents, 
used currently as experimental models of this disease. These 
facts support the hypothesis that the proposed enzymes, 
although related to the DNA of the parasite, can be expressed in 
the S. mansoni membrane and excrete by some pathway, what 
can cause a specific activation during the schistosomiasis.  
 
II. MATERIAL AND METHODS 
 
A. Obtention of PNP1, HGPRT and ADK1 recombinant 
enzymes 
 
The recombinant enzymes were synthesized by the insertion of 
plasmids in bacterial cultures. To do so, the protein expression 
methodology was used. The enzymes were purified through the 
method of affinity chromatography. The used methodology for 
the obtention of the PNP1 enzyme was according to Pereira [25] 
and, for the obtention of the HGPRT and ADK1 enzymes, 
according to Romanello [37] conducted at the Cristallography 
Laboratory of the São Carlos Institute of Physics – IFSC, 
located at University of São Paulo, Brazil – USP, São Carlos – 
SP – Brazil, under the coordination of Dr. Humberto D’ Muniz 
Pereira and the supervision of Prof. Dr. Richard C. Garratt, both 
belonging to the CBME-IFSC-USP.  
 
B. Animals 
 
Female mice of Balb/c lineage and specific pathogen free (SPF), 
weighing between 15 and 18 grams, were brought from the 
CEMIB of the University of Campinas (UNICAMP), Brazil. 
The mice were kept in proper cages in the experimentation 
vivarium of the Department of Morphology and Pathology, 
Federal University of São Carlos, Brazil with free access to 
potable water and standard commercial diet. The experimental 
delineation of this work was based upon the recommendations 
of the Animal Experimentation Ethical Principles, adopted by 
the Brazilian Society of Laboratory Animals Science (SBCAL) 
and was submitted and approved by the Ethics Commission in 
Animal Experimentation  (CEEA) of the Federal University of 
São Carlos, No. 12/2010. 
 
C. Obtention of the Schistosoma mansoni infectant larvae 
(cercariae) 
 
The larvae (cercariae), strain LE (BH-MG), were gently given 
by Prof. Dr. Vanderlei Rodrigues of the Department of 
Biochemistry and Immunology, University of São Paulo- 
(FMRP/USP). The larvae were removed from S. 
mansoni-infected Biomphalaria glabrata snails, which were 
kept in the moluscario of the aforementioned  institution. 
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D. Mice infection with Schistosoma mansoni infectant larvae 
(cercariae) 
 
The mice were infected using subcutaneous route (s.c.) with S. 
mansoni larvae. They were inoculated about 50 cercariae /0,3 
mL of 0,9% NaCl/animal physiological solution, with the aid of 
a 1 ml syringe. This volume and concentration (physiological 
solution) are unable to affect the cercariae’s viability. The 
method of infection was standardized by the laboratory 
technician Olinda Mara Brigoto of the Department of 
Biochemistry and Immunology, University of São Paulo 
(FMRP/USP). 
 
E. Mice immunization 
 
After the purification of the recombinant enzymes, 100ug (for 
each enzyme) were added in 200µL of sterile PBS, containing 
100µg of aluminum hydroxide (Dinâmica lote 35044) and 
applied into the mice through intraperitoneal route (i.p) thrice 
in 15-day intervals. After 15 days since last immunization, the 
mice were infected with 50 S. mansoni cercariae/animal. This 
stage of the research consisted of the creation of the following 
experimental groups: control group, no immunization of any 
kind received (n=6/experiment), only infected group and the 
immunized (PNP1 or HGPRT or ADK1) and infected group 
(n=10/experiment/each enzyme). Two independent 
experiments were carried. The mice were euthanized on the 48
th 
and 85
th 
days post-infection with overdose of Thionembutal 
anesthetic (North Chicago, Illinois, USA). The blood was 
obtained by cardiac puncture with the aid of a syringe with 
anticoagulant (EDTA). The serum was obtained after 
centrifugation of the total extracted blood, in a speed of 1500 
rpm, for a 15-minute period. 
  
F. Immunoenzimatic assay – Indirect ELISA – Antibodies 
detection 
 
An ELISA (BD KIT) was performed to detect 
immunoglobulins. To detect IgG/ IgG2a, 5µg/mL of the total 
antigen’s protein was added to the 90-well plate’s  sensitization 
and 1:64, IgE, 10 mg / ml of total protein antigen of adult worm 
and sample dilution 1:4). The protein extract of S. mansoni 
antigens was gently prepared by the student Ricardo Oliveira 
Correia (LAP-DMP-UFSCar), in accordance with Rofatto [38]. 
Thus, for the detection of immunoglobulin in plasma, 96-well 
micro plates were used, coated with 5 or 10µg/mL of S. 
mansoni total antigen’s protein (diluted in carbonate buffer 
0.1M and applied 100µL/well). After the plates have been 
washed with PBS-Tween 20 0,05%, 200µL of blocking buffer 
(PBS-BSA 1%) was added and kept for one hour at room 
temperature. The plates were then washed once again and 50µL 
of the samples were added, diluted in carbonate buffer (1:64 for 
IgG/IgG2a and 1:4 IgE), being kept at room temperature for 2 
hours. Once again, the plates were washed and 100µL of biotin 
conjugated secondary antibody (4 μL Ac + 10 mL of carbonate 
buffer) was added. After 1 hour, the plates were washed again 
and 100µL of streptavidin enzyme were added (1:200 dillution). 
After 30 minutes, the plate was washed and 100µL of the 
substratum, a 1:1 mixture of H2O2  and tetramethylbenzidine 
(TMB) (BD-OpTEIA),  were added.  The reaction was then 
blocked with 50µL/well of  H2SO4 1M. The absorbance reading 
was performed in 450nm wave length in ELISA reader 
(MicroQuant-Sellex,Inc.). 
 
G. Statistical analysis 
 
The results were expressed as means and standard deviations. 
Data from pairs of groups were analyzed using the 
Mann-Whitney U test; and data from multiple groups were 
analyzed using the ANOVA test followed by a multiple 
comparison test (Bonferroni’s Multiple Comparison Test) 
(Prism 5.0 software). 
 
III. Results 
 
A. Humoral response evaluation at 48
th 
day post-infection 
 
Results of imunoenzimatic assay – ELISA indicate that levels 
of antibodies were produced at 48
th
 day post-infection. Figure 1 
represents the optical density (O.D.) of IgG, IgG2a and IgE 
antibodies, reactive to adult worms antigens, present in the 
plasma of the animals of the following groups: no 
immunization/infected, immunized with PNP 
enzymes/infected, immunized with HGPRT/infected and 
immunized with ADK/infected, at the 48
th
 day post-infection. 
An IgG increase was observed in the immunized with HGPRT 
enzyme/infected group, when compared to the control group. 
As for the detection of IgG2a production in the immunized with 
HGPRT enzyme/infected group and ADK groups presented 
significant increase when compared to the control group. 
Relative to detection of IgE production, the immunized with the 
HGPRT enzyme/infected and ADK enzyme/infected groups 
showed a significant increase when compared to the control 
group. The PNP, however, didn’t present a significant increase 
when compared to the control group.  
 
B. Humoral response evaluation at 85
th 
day post-infection 
 
At the 85
th
 day post-infection (figure 2), it was observed that the 
immunized with PNP enzyme/infected and HGPRT 
enzyme/infected groups presented significant increase of IgG 
when compared to the control group. As for the immunized 
with ADK enzyme/infected group, no significant increase of 
IgG was observed, when compared to the control group. 
For the detection of IgG2a, the immunized with HGPRT 
enzyme/infected and ADK enzyme/infected groups showed 
significant increase when compared with the control group. The 
immunized with PNP enzyme/infected group, however, didn’t 
present a significant increase of IgG2a when compared to the 
control group. For the detection of IgE production, the 
immunized with HGPRT enzyme/infected and ADK 
enzyme/infected groups presented significant increase when 
compared to the control group. The immunized with PNP 
enzyme group, however, didn’t present significant increase in 
antibodies production in this period. 
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IV. DICUSSION 
 
Schistosomiasis is an infection of worldwide importance, 
affects a great number of people and promotes socioeconomic 
impairment. Despite the existence of drugs against adult worms, 
there is deficiency of drugs which can control the morbid 
effects of infection or even vaccines which can control the 
parasite’s dissemination. Even though the Health Ministry has 
made available a vaccine for tests in humans, in 2012, its 
efficiency is still debatable. It is known that the parasites induce 
weak natural immunity and are capable of evading or resisting 
the host`s specific immune responses active. This persistence 
leads to chronic immune reactions, resulting in tissue injury and 
pathologic complications. These complications are more 
related to the host’s immune response to the parasite and eggs 
than to the infection itself [39]. During the infection, the host’s 
immune response against cercarie and schistosomula is initially 
measured by Th1 type cells. As the infection progresses, the 
response is modulated by Th2 cells, induced particularly during 
the formation of granulomas, which were generated by antigens 
of eggs that were retained in the host’s tissues [40].  
Considering the humoral immune response, it has been shown 
that the classes and subclasses of anti-Schistosoma vary with 
the age, infection intensity and, possibly, with the duration of 
infection [41]. Some studies have shown that the composition 
of isotypes of antibodies against Schistosoma may strongly 
influence on the efficiency of effector mechanisms of 
antibody-dependent cellular cytotoxicity (ADCC) and, 
consequently, on the expression of protective immunity or 
pathology [42]. Antibody-dependent, cell-mediated 
cytotoxicity is considered an important defense mechanism 
against schistosomula, which involves IgG and IgE antibodies 
and various cell types, including T cells, eosinophils and 
neutrophils [43, 44 apud  45].  
One of the strategies to produce vaccines against S. mansoni 
considers the use of the recombinant proteins. Already in 
clinical testing, the membrane protein Sm TSP-1 found in the 
tegument apical membrane of the parasite, after immunization, 
induced a reduction of 30-50% in the parasite load against adult 
worms and a reduction in more than 50% against the eggs [46]. 
The paramyosin Sm97, a protein from the schistosomula 
tegument and from the musculature of adult worms, induced an 
action against adult worms, decreasing by 30-50% in the 
parasite load and promoting the production of IgG and IgE 
[47,48]. Thus, these data support our hypothesis that using 
recombinant proteins from the S. mansoni, independently of the 
parasite origin, may assist us in the search for tools that 
effectively contribute in the control of schistosomiasis 
mansoni. 
 Anaphylactic antibodies have been associated with the 
expression of immunity. These antibodies of isotypes IgE and 
some of IgG subclasses are directly involved in the killing of 
schistosomules, in vitro, in association with populations of 
effector cells, such as macrophages, eosinophils and platelets. 
Furthermore, these antibodies induce a high level of protection 
against new exposures to cercariae, when passively transferred 
to mice not infected [49]. The studied enzymes present 
different identities, compared to humans’ enzymes, being the 
PNP enzyme the closest, with an identity of 50%. Recently, this 
study’s collaborator group (IFSC-USP) showed that the 
enzymes’ structures (PNP/HGPRT/ADK) don’t pose a risk in 
human immunization, as the highest percentages of homology 
were of 30-40% of identity with the same enzymes in humans. 
The obtained results suggest that the enzymes were 
immunogenic in order to stimulate an increase on the 
production of the anti- S. mansoni antibodies in the 
schistosomiasis experimental model. There is a family of S. 
mansoni proteins, with molecular weight of 20 kDa, which was 
associated with the host’s resistance against reinfection, being 
the resistance correlated with IgE production induced by these 
antigens. In our tests for detection of IgE production in the 
immunized animals’ plasma, we verified that the immunized 
with HGPRT enzyme/infected and ADK enzyme/infected 
groups increased IgE production at the 48
th
 and 85
th
 days 
post-infection (Figure 1C/2C). There are reports relating the 
age-acquired resistance of individuals from endemic regions 
and reinfection during schistosomiasis mansoni with an 
IgE-mediated response [50]. In our tests for detection of IgE in 
the plasma of animals from the immunized with HGPRT 
enzyme/infected and ADK enzyme/infected groups, we 
verified a significant IgE production at the 48
th
 and 85
th
 days 
post-infection, when compared to the control group. In this 
respect, this suggests that these enzymes can be associated to 
the Th2 response pattern induced in the host by the parasites, 
and that immunization with these enzymes could contribute to 
that Th2 response. However, IgE levels against certain antigens 
is a characteristic in resistant individuals from endemic area, 
and it is worth mentioning that some studies report the idea that 
an antigen, to be effective against schistosomiasis mansoni, 
must also be capable of increasing IgE antibodies [51]. 
Moreover, it was described that the eggs from S. mansoni lead 
to the release of IL-4, contributing to the IgE secretion [52]. 
The immunized with HGPRT enzyme/infected and ADK 
enzyme/infected groups (Figure 2) presented an IgG2a 
production only at the 85
th
 day post-infection. In face of these 
facts, it emerged the hypothesis that the proposed enzymes, 
despite being related to the parasite’s ADN can be expressed in 
the S. mansoni membrane and secreted by some pathway. The 
results presented in this study suggest that these antigens, the S. 
mansoni PNP and HGPRT recombinant enzymes, can play a 
role in the schistosomiasis prevention. It is necessary, however, 
further studies in order to comprehend the immune mechanism 
involved in the antibodies production from the mentioned 
enzymes in this experimental model.  
 
V. CONCLUSION   
 
Ours results suggested that the recombinant enzymes 
immunization was helpful the increase for the specific immune 
response by antibody, in the future has been possibility as 
immunogenic proteins target against schistosomiasis protection. 
Future work may concentration on evaluation of the use of 
theses enzymes on the schistosomiasis murine model for the 
cooperation with other studies by eradication schistosomal 
infection in the world. 
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Figure 1. Detection of antibodies in the plasma of 
immunized animals at 48
th
 day post-infection. Detection of 
IgG (A); IgG2a (B) and IgE (C) in plasma. Data represent mean 
± EPM (n= 10 animals) of 2 independent experiments. The 
symbol * (p < 0,05) represents the significant difference 
between the results obtained from the immunized/infected 
groups when compared to the control group, using the 
nonparametric one-way ANOVA Tukey's test.    
 
 
 
Figure 2. Dosage of antibodies in the plasma of immunized 
animals at 85
th
 day post-infection. Dosage of IgG (A); IgG2a 
(B) and IgE (C) in plasma. Data represent mean ± EPM (n= 10 
animals) of 2 independent experiments. The symbol * (p < 0,05) 
represents the significant difference between the results 
obtained from the immunized/infected groups when compared 
to the control group, using the nonparametric one-way 
ANOVA Tukey's test. 
 
 
 
 
 
 
